Metformin hydrochoride — Competitive Intelligence Brief

Metformin hydrochoride (Metformin hydrochoride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

marketed Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase Diabetes Small molecule

Target snapshot

Metformin hydrochoride (Metformin hydrochoride) — University of Massachusetts, Worcester. Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in type 2 diabetes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metformin hydrochoride TARGET	Metformin hydrochoride	University of Massachusetts, Worcester	marketed	Biguanide	AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
Metformin and Saxagliptin	Metformin and Saxagliptin	ikfe-CRO GmbH	marketed	Biguanide + DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Saxagliptin: DPP-4 (dipeptidyl peptidase-4)
Telmisartan plus Metformin	Telmisartan plus Metformin	Third Military Medical University	marketed	ARB + Biguanide combination	Angiotensin II type 1 receptor (AT1R); mitochondrial glycerophosphate dehydrogenase
DPP-4 inhibitor + metformin group	DPP-4 inhibitor + metformin group	Beni-Suef University	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase
Metformin IR	Metformin IR	AstraZeneca	marketed	Biguanide	AMP-activated protein kinase (AMPK)
MET	MET	Ente Ospedaliero Ospedali Galliera	marketed	Biguanide	AMP-activated protein kinase (AMPK) / mitochondrial complex I
Placebo-Metformin	Placebo-Metformin	Steno Diabetes Center Copenhagen	marketed	Biguanide	AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

1. AstraZeneca · 4 drugs in this class
2. Merck Sharp & Dohme LLC · 3 drugs in this class
3. University of Texas Southwestern Medical Center · 2 drugs in this class
4. Mount Sinai Hospital, Canada · 2 drugs in this class
5. GlaxoSmithKline · 2 drugs in this class
6. Eli Lilly and Company · 2 drugs in this class
7. University Magna Graecia · 2 drugs in this class
8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class